Scholarlink

<p>This exploratory, single-group, open-label study investigated 17 patients with Parkinson’s disease (PD) using a pre-post design. Motor and non-motor outcomes were assessed through clinical scales, biochemical and genetic analyses, and machine learning models (Gradient Boosting Machines, Random Forests). After treatment with a neurotrophic peptide mixture, improvements were observed in daily activity (16%), cognition (11%), depression (10% reduction), and reactive anxiety (23% reduction). Biological changes included a 45% increase in platelet δ-granules, higher mitochondrial counts, elevated gene expression (notably BDNF in women, p = 0.046), and modulation of oxidative stress markers (17% reduction in TBARS, 30% increase in GSH). Machine learning identified BDNF and PINK1 expression, along with MOCA and MMSE scores, as key predictors of UPDRS improvement. These findings suggest that neurotrophic peptide therapy may influence clinical, structural, and molecular domains in PD. Larger, controlled trials are warranted to confirm therapeutic potential and clarify associations with cognitive and neurotrophic parameters.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluation of the neurotrophic peptide mixture in pathogenetic therapy of patients with Parkinson’s disease

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月23日

查看全文
  • Dmytro Krasnienkov,
  • Iryna Karaban,
  • Nina Karasevych,
  • Nataliia Melnyk,
  • Sergiy Kryzhanovskyi,
  • Kateryna Rozova,
  • Olga Gonchar,
  • Iryna Mankovska,
  • Sofiia Smovzh,
  • Kostiantyn Midlovets,
  • Olexiy Barsukov,
  • Oksana Zabuha,
  • Tetiana Papurina

摘要

This exploratory, single-group, open-label study investigated 17 patients with Parkinson’s disease (PD) using a pre-post design. Motor and non-motor outcomes were assessed through clinical scales, biochemical and genetic analyses, and machine learning models (Gradient Boosting Machines, Random Forests). After treatment with a neurotrophic peptide mixture, improvements were observed in daily activity (16%), cognition (11%), depression (10% reduction), and reactive anxiety (23% reduction). Biological changes included a 45% increase in platelet δ-granules, higher mitochondrial counts, elevated gene expression (notably BDNF in women, p = 0.046), and modulation of oxidative stress markers (17% reduction in TBARS, 30% increase in GSH). Machine learning identified BDNF and PINK1 expression, along with MOCA and MMSE scores, as key predictors of UPDRS improvement. These findings suggest that neurotrophic peptide therapy may influence clinical, structural, and molecular domains in PD. Larger, controlled trials are warranted to confirm therapeutic potential and clarify associations with cognitive and neurotrophic parameters.